Drugs / Quetiapine fumarate extended release (Quetiapine XR)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01165541 | Sep 2010 → Oct 2012 | alcohol dependence | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quetiapine fumarate extended release (Quetiapine XR) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01165541 ↗ |
| Known as | quetiapine XR, Seroquel XR | “quetiapine XR, Seroquel XR” NCT01165541 ↗ |
| Action | Inhibit | “Quetiapine is a weak D2 antagonist and a moderate alpha 2 receptor antagonist” NCT01165541 ↗ |